Author

Natália Aniceto

Researcher at iMed.ULisboa, University of Lisbon - Cited by 298 - Machine Learning - Drug development - QSAR - Applicability Domain

Biography

Dr Natalia Aniceto is working as an Assistant Professor at Lusophone University of Humanities and Technologies, Lisboa, Portugal. He is having experience of more than 10 years and he had attended many International Conferences and chair the sessions.
Title
Cited by
Year
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
AHC Vlot, N Aniceto, MP Menden, G Ulrich-Merzenich, A BenderDrug discovery today 24 (12), 2286-2298, 2019201
62
2019
49
2016
Conformal Regression for Quantitative Structure–Activity Relationship Modeling—Quantifying Prediction Uncertainty
F Svensson, N Aniceto, U Norinder, I Cortes-Ciriano, O Spjuth, L Carlsson, ...Journal of Chemical Information and Modeling 58 (5), 1132-1140, 2018201
49
2018
Ibuprofen Nanoparticles for Oral Delivery: Proof of Concept
CP Reis, JP Ferreira, S Candeias, C Fernandes, N Martinho, N Aniceto, ...Journal of Nanomedicine & Biotherapeutic Discovery 4 (1), 1, 2014201
29
2014
Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition
H Brito, V Marques, MB Afonso, DG Brown, U Börjesson, N Selmi, ...Cell death discovery 6 (1), 1-13, 2020202
16
2020
Prediction of drug distribution in rat and humans using an artificial neural networks ensemble and a PBPK model
P Paixão, N Aniceto, LF Gouveia, JAG MoraisPharmaceutical research 31 (12), 3313-3322, 202
14
2014
Pyrazoles as novel protein tyrosine phosphatase 1B (PTP1B) inhibitors: An in vitro and in silico study
S Rocha, M Lucas, VLM Silva, PMO Gomes, AMS Silva, AN Araújo, ...International Journal of Biological Macromolecules 181, 1171-1182, 2021202
12
2021
Simultaneous Prediction of four ATP-binding Cassette Transporters’ Substrates Using Multi-label QSAR
N Aniceto, AA Freitas, A Bender, T GhafourianMolecular Informatics, 2016201
10
2016
Chemical patterns of proteasome inhibitors: Lessons learned from two decades of drug design
RA Guedes, N Aniceto, MAP Andrade, JAR Salvador, RC GuedesInternational journal of molecular sciences 20 (21), 5326, 20120
9
2019
The antitumor effects of an arsthinol–cyclodextrin complex in a heterotopic mouse model of glioma
S Becherirat, MC Lanhers, M Socha, M Yemloul, A Astier, C Loboda, ...European Journal of Pharmaceutics and Biopharmaceutics 5 (3), 560-56, 2013201
8
2013
Tissue-to-blood distribution coefficients in the rat: utility for estimation of the volume of distribution in man
P Paixão, N Aniceto, LF Gouveia, JAG MoraisEuropean Journal of Pharmaceutical Sciences 50 (3-4), 526-543, 2013201
8
2013
Melanoma Prevention: Challenges and Progresses in Nanotechnology for Melanoma Prevention and Treatment
CO Silva, N Martinho, N Aniceto, CP ReisCRC Concise Encyclopedia of Nanotechnology, 2015201
6
2015
An In Silico and an In Vitro Inhibition Analysis of Glycogen Phosphorylase by Flavonoids, Styrylchromones, and Pyrazoles
S Rocha, N Aniceto, RC Guedes, HMT Albuquerque, VLM Silva, ...Nutrients 14 (2), 30, 2022202
6
2022
Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport
M Michaelis, F Rothweiler, M Wurglics, N Aniceto, M Dittrich, H Zettl, ...Oncotarget 7 (10), 11664, 2016201
5
2016
Exploring the Chemical Space of Urease Inhibitors to Extract Meaningful Trends and Drivers of Activity
N Aniceto, VDB Bonifácio, RC Guedes, N MartinhoJournal of Chemical Information and Modeling, 2022202
4
2022
Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma
FGA Estrada, S Miccoli, N Aniceto, AT García-Sosa, RC GuedesMolecules 26 (8), 5574, 20220
1
2021